title: Influence of bovine serum albumin on the secondary structure of interferon alpha 2b as determined by far UV circular dichroism spectropolarimetry.
abstract: Many therapeutic biologics are formulated with excipients, including the protein excipient human serum albumin (HSA), to increase stability and prevent protein aggregation and adsorption onto glass vials. One biologic formulated with albumin is interferon alpha-2b (IFN alpha-2b). As is the case with other therapeutic biologics, the increased structural complexity of IFN alpha-2b compared to a small molecule drug requires that both the correct chemical structure (amino acid sequence) and also the correct secondary and tertiary structures (3 dimensional fold) be verified to assure safety and efficacy. Although numerous techniques are available to assess a biologic's primary, secondary and tertiary structures, difficulties arise when assessing higher order structure in the presence of protein excipients. In these studies far UV circular dichroism spectropolarimetry (far UV-CD) was used to determine the secondary structure of IFN alpha-2b in the presence of a protein excipient (bovine serum albumin, BSA). We demonstrated that the secondary structure of IFN alpha-2b remains mostly unchanged at a variety of BSA to IFN alpha-2b protein ratios. A significant difference in alpha helix and beta sheet content was noted when the BSA to IFN alpha-2b ratio was 5:1 (w/w), suggesting a potential conformational change in IFN alpha-2b secondary structure when BSA is in molar excess.
authors.affiliation: Centre for Biologics Research, Biologics and Genetic Therapies Directorate, Health Canada, 251 Sir Frederick Banting Driveway, Ottawa, ON K1A 0K9, Canada. michael_johnston@hc-sc.gc.ca
authors.forename: Michael J W
authors.initials: MJ
authors.lastname: Johnston
authors.forename: Kayla
authors.initials: K
authors.lastname: Nemr
authors.forename: Mary A
authors.initials: MA
authors.lastname: Hefford
mesh_terms: D000818:Animals; D002417:Cattle; D002942:Circular Dichroism / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D005079:Excipients / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000737:chemistry* / Q000187:drug effects*; D009994:Osmolar Concentration; D011489:Protein Denaturation / Q000187:drug effects; D017510:Protein Folding / Q000187:drug effects; D017433:Protein Structure, Secondary / Q000187:drug effects; D011994:Recombinant Proteins; D012710:Serum Albumin, Bovine / Q000009:adverse effects / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013816:Thermodynamics; D014466:Ultraviolet Rays
chemical_list: D005079:Excipients; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012710:Serum Albumin, Bovine